Search hospitals > Louisiana > New Orleans
Tulane University School of Medicine
Claim this profileNew Orleans, Louisiana 70112
Global Leader in Skin Cancer
Global Leader in T-Lymphoblastic Leukemia/Lymphoma
Conducts research for Human Immunodeficiency Virus Infection
Conducts research for Antiretroviral Therapy
Conducts research for Prostate Cancer
284 reported clinical trials
38 medical researchers
Summary
Tulane University School of Medicine is a medical facility located in New Orleans, Louisiana. This center is recognized for care of Skin Cancer, T-Lymphoblastic Leukemia/Lymphoma, Human Immunodeficiency Virus Infection, Antiretroviral Therapy, Prostate Cancer and other specialties. Tulane University School of Medicine is involved with conducting 284 clinical trials across 995 conditions. There are 38 research doctors associated with this hospital, such as Pedro M. Barata, Nakhle Saba, Christopher R. Trevino, and Kendra M. Harris.Area of expertise
1Skin Cancer
Global LeaderStage IV
Stage III
Stage II
2T-Lymphoblastic Leukemia/Lymphoma
Global LeaderStage II
t(8;21)(q22;q22) positive
t(16;16)(p13;q22) positive
Top PIs
Pedro M. BarataTulane University Health Sciences Center1 year of reported clinical research
Studies Skin Cancer
Studies Kidney Cancer
20 reported clinical trials
52 drugs studied
Nakhle SabaTulane Cancer Center7 years of reported clinical research
Expert in Lymphoma
Studies Diffuse Large B-Cell Lymphoma
17 reported clinical trials
42 drugs studied
Christopher R. TrevinoTulane University Health Sciences Center8 years of reported clinical research
Studies Glioblastoma
Studies Uterine Tumors
12 reported clinical trials
39 drugs studied
Kendra M. HarrisTulane University Health Sciences Center7 years of reported clinical research
Studies Skin Cancer
Studies Stomach Cancer
11 reported clinical trials
35 drugs studied
Clinical Trials running at Tulane University School of Medicine
Prostate Cancer
Kidney Cancer
Bladder Carcinoma
Bladder Cancer
Multiple Myeloma
Stroke
Kidney Carcinoma
Plasma Cell Neoplasm
Skin Cancer
Renal Cell Carcinoma
Hormone + Radiation Therapy
for Prostate Cancer
This phase III trial compares less intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in treating patients with high risk prostate cancer and low gene risk score. This trial also compares more intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in patients with high risk prostate cancer and high gene risk score. Apalutamide may help fight prostate cancer by blocking the use of androgen by the tumor cells. Radiation therapy uses high energy rays to kill tumor cells and shrink tumors. Giving a shorter hormone therapy treatment may work the same at controlling prostate cancer compared to the usual 24 month hormone therapy treatment in patients with low gene risk score. Adding apalutamide to the usual treatment may increase the length of time without prostate cancer spreading as compared to the usual treatment in patients with high gene risk score.
Recruiting2 awards Phase 36 criteria
Apalutamide + Hormone and Radiation Therapies
for Prostate Cancer
This phase III trial studies whether adding apalutamide to the usual treatment improves outcome in patients with lymph node positive prostate cancer after surgery. Radiation therapy uses high energy x-ray to kill tumor cells and shrink tumors. Androgens, or male sex hormones, can cause the growth of prostate cancer cells. Drugs, such as apalutamide, may help stop or reduce the growth of prostate cancer cell growth by blocking the attachment of androgen to its receptors on cancer cells, a mechanism similar to stopping the entrance of a key into its lock. Adding apalutamide to the usual hormone therapy and radiation therapy after surgery may stabilize prostate cancer and prevent it from spreading and extend time without disease spreading compared to the usual approach.
Recruiting2 awards Phase 3
Immunotherapy + Targeted Therapy
for Genitourinary Cancers
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the body. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib, nivolumab, and ipilimumab may work better in treating patients with genitourinary tumors that have no treatment options compared to giving cabozantinib, nivolumab, or ipilimumab alone.
Recruiting1 award Phase 221 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Tulane University School of Medicine?
Tulane University School of Medicine is a medical facility located in New Orleans, Louisiana. This center is recognized for care of Skin Cancer, T-Lymphoblastic Leukemia/Lymphoma, Human Immunodeficiency Virus Infection, Antiretroviral Therapy, Prostate Cancer and other specialties. Tulane University School of Medicine is involved with conducting 284 clinical trials across 995 conditions. There are 38 research doctors associated with this hospital, such as Pedro M. Barata, Nakhle Saba, Christopher R. Trevino, and Kendra M. Harris.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.